Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05640843 · ClinicalTrials.gov registry record · NA
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
A NA study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 8
- Study locations
NCT05640843: Recruiting NA study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05640843 is a NA study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 150 participants, below the 792-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (81% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05640843, a NA study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 8
- Study locations
Study Summary
The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.
Primary Outcome
To evaluate the change in stool microbiome diversity on a dietary vs supplement vs placebo intervention at 12 weeks when compared to baseline
Conditions Studied
Interventions
- OTHER Whole Foods Plant-based Diet
- DIETARY_SUPPLEMENT Algae Omega 3 + Curcumin
- OTHER Placebo supplements
Study Locations (8)
New York
- Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Georgia
- Emory University (Data Collection Only) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-11-29 |
| Est. Completion | 2026-11 |
| Phase | NA |
What NCT05640843 shows while recruiting
NCT05640843 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 792-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Whole Foods Plant-based Diet is the first listed.
NCT05640843 lists 8 locations in 3 states (New York, New Jersey, Georgia).
Frequently Asked Questions
What is clinical trial NCT05640843 about?
NCT05640843 is a clinical study titled "A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)". The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare ho...
What is the current status of trial NCT05640843?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2022-11-29. Estimated completion is 2026-11.
What conditions does trial NCT05640843 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance.
What interventions are being tested in trial NCT05640843?
The interventions under investigation include: Whole Foods Plant-based Diet (OTHER), Algae Omega 3 + Curcumin (DIETARY_SUPPLEMENT), Placebo supplements (OTHER).
Who is sponsoring clinical trial NCT05640843?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05640843 being conducted?
This trial has 8 study locations across Georgia, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05640843's enrollment target sits among peer trials
150 10th of 20 higher than 11 of 20 other Smoldering Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
ACTIVE NOT RECRUITING · NA
-
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
ACTIVE NOT RECRUITING · NA
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
RECRUITING
-
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
RECRUITING
-
Registry for Adults With Plasma Cell Disorders (PCD's)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI